Highlights

  • Oneview Healthcare (ASX:ONE) provides patient-engagement software to hospitals across international markets.
  • Its Care Experience Platform integrates entertainment, education, meal ordering and care information into hospital workflows.
  • The Epic MyChart Bedside TV integration provides a potential new commercial channel for the company.
  • Future progress will depend on hospital adoption, recurring-revenue growth and the pathway toward sustainable profitability.

Oneview Healthcare (ASX:ONE) occupies a distinctive corner of the ASX health sector: a Dublin-based digital-health company whose CHESS Depositary Interests have traded in Sydney since 2016, selling patient-engagement software into hospitals rather than drugs or devices. That makes it a technology growth story wrapped in a healthcare label, and one where the path to sustained profitability is the central question for investors.

The company's Care Experience Platform runs on bedside and mobile screens, giving patients, families and clinical staff access to entertainment, education, meal ordering and care information, and integrating with hospitals' electronic medical record systems. Oneview positions the platform as a way for health systems to lift patient experience scores while easing pressure on stretched nursing staff.

The latest strategic step

The most concrete recent development came on 20 May 2026, when Oneview Healthcare (ASX:ONE) announced that its Bedside Hub product would power Epic MyChart Bedside TV, describing it as a new Revenue channel delivering a "fully managed bedside experience."

The integration positions Oneview as the managed-experience layer for the bedside offering and is strategically meaningful for a company of its size. The announcement did not disclose customer names or contract values, so the commercial scale of the channel remains to be proven in subsequent reporting.

Why the market is watching

The appeal is a recurring-revenue software model addressing a real problem in hospitals, with an international installed base and a foothold in the demanding US market. Oneview's technology has been deployed across more than 80 hospitals internationally, giving it reference sites that matter in a sector where procurement is slow and relationship-driven.

The risk profile is equally clear. Oneview Healthcare (ASX:ONE) has historically been loss-making, with negative earnings per share, and it pays no dividend, so the Business case depends heavily on growth and an eventual move toward sustainable profitability.

Its register is concentrated, with investor Will Vicars associated with a holding of roughly 40 per cent, which can influence Liquidity and control dynamics. Hospital IT budgets are also cyclical and subject to long sales cycles, meaning revenue can be lumpy even when the pipeline looks healthy.

Catalysts and risks ahead

Investors will be looking for evidence that the Epic MyChart Bedside channel converts into signed hospitals and recurring revenue, alongside broader growth in the platform's installed base and recurring-revenue metrics in quarterly cash-flow and results updates.

Cash runway remains an important consideration for a company that has needed to fund growth ahead of profitability. Commentary on the Balance Sheet and the timing of cash-flow breakeven will therefore remain relevant to sentiment around the business.

The key risks are competition from larger patient-engagement and clinical-communication vendors, dependence on a relatively small number of large hospital contracts, execution risk in scaling new channels, and the funding risk inherent in a still-unprofitable business. Currency exposure also matters given the mismatch between an Australian listing and largely US and European operations.

A balanced view

Oneview Healthcare (ASX:ONE) sits at the higher-risk, higher-optionality end of the ASX health-tech spectrum. The Epic integration is a meaningful strategic marker rather than a transformational contract on its known terms, and the Investment case ultimately rests on converting its reference base into scalable, recurring revenue.

For now, the product proposition appears established, while the commercial and financial proof is still being assembled. Future results will be important in showing whether new channels can translate into broader hospital adoption, recurring-revenue growth and a clearer pathway toward sustainable profitability.